Blood Tests, Radiopharmaceuticals, and a Viagra Surprise: Cancer Medicine's Breakthrough Week

The FDA has approved SimpleScreen, a groundbreaking blood test that detects 80% of colorectal cancers — the second-leading cause of U.S. cancer deaths — using just a standard blood draw. Made by California biotech Freenome, the test targets adults aged 45 and older at average risk, offering results in roughly two weeks. It joins Guardant Health's Shield test (approved in 2024) as only the second FDA-cleared blood-based colorectal cancer screening option. The urgency is...